表紙
市場調查報告書

藥物分析:Opdivo

Opdivo

出版商 Datamonitor Healthcare 商品編碼 603944
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Opdivo Opdivo
出版日期: 2019年09月09日內容資訊: 英文 118 Pages
簡介

本報告提供免疫查核點抑制劑Opdivo的相關調查,提供主要國家/地區的銷售額實際成果與預測,就各疾病來看的藥物評估·SWOT分析,及藥物簡介等資訊。

  • 產品簡介
  • Opdivo:大腸癌 (CRC)
  • Opdivo:頭頸癌
  • Opdivo:肝癌 (HCC)
  • Opdivo:膀胱癌
  • Opdivo:神經膠質母細胞瘤 (GBM)
  • Opdivo:腎細胞癌 (RCC)
  • Opdivo:非小細胞肺癌 (NSCLC)
  • Opdivo:胃癌
  • Opdivo:黑色素瘤

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0093240

Drug Overview:

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells. PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation 28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. Blocking the interaction of the PD-1 receptor with its ligands may allow T cells to restore an anti-tumor immune response.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Opdivo: Hepatocellular carcinoma (HCC)
    • Opdivo: Renal cell carcinoma (RCC)
    • Opdivo: Non-small cell lung cancer (NSCLC)
    • Opdivo: Melanoma
    • Opdivo: Gastric cancer
    • Opdivo: Colorectal cancer (CRC)
    • Opdivo: Head and neck cancer
    • Opdivo: Bladder cancer

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Opdivo for HCC
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Opdivo for HCC
  • Figure 3: Opdivo sales for HCC across the US and five major EU markets, by country, 2018-27
  • Figure 4: Opdivo for RCC - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment summary of Opdivo for RCC
  • Figure 6: Datamonitor Healthcare's drug assessment summary of Opdivo for RCC
  • Figure 7: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 8: Opdivo for non-small cell lung cancer - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 10: Datamonitor Healthcare's drug assessment summary for Opdivo in non-small cell lung cancer
  • Figure 11: Opdivo sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 12: Opdivo for melanoma - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Opdivo for melanoma
  • Figure 15: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 16: Opdivo for gastric cancer - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Opdivo for gastric cancer
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Opdivo for gastric cancer
  • Figure 19: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 20: Opdivo for colorectal cancer - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Opdivo for colorectal cancer
  • Figure 23: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
  • Figure 24: Opdivo for head and neck cancer - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Opdivo for SCCHN
  • Figure 27: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 28: Opdivo for urothelial bladder cancer - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer
  • Figure 30: Datamonitor Healthcare's drug assessment summary for Opdivo in urothelial bladder cancer

LIST OF TABLES

  • Table 1: Recent high-impact events for Opdivo in HCC
  • Table 2: Opdivo drug profile
  • Table 3: Approval history of Opdivo for HCC in the US, Japan, and five major EU markets
  • Table 4: Trials of Opdivo for HCC
  • Table 5: Opdivo for HCC - SWOT analysis
  • Table 6: Opdivo drug profile
  • Table 7: Opdivo Phase III data in RCC
  • Table 8: Opdivo ongoing trials in RCC
  • Table 9: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Opdivo drug profile
  • Table 11: Opdivo pivotal trial data in non-small cell lung cancer
  • Table 12: Opdivo CheckMate-026 Phase III data in non-small cell lung cancer
  • Table 13: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 14: Opdivo sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 15: Opdivo patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 16: Opdivo drug profile
  • Table 17: Opdivo pivotal trial data in melanoma
  • Table 18: Opdivo ongoing late-phase clinical trials in melanoma
  • Table 19: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 20: Opdivo patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 21: Opdivo drug profile
  • Table 22: Opdivo pivotal trial data in gastric cancer
  • Table 23: Opdivo Phase III trials in gastric cancer
  • Table 24: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 25: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 26: Opdivo drug profile
  • Table 27: Opdivo pivotal trial data in colorectal cancer
  • Table 28: Opdivo early-phase trials in colorectal cancer
  • Table 29: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
  • Table 30: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
  • Table 31: Opdivo drug profile
  • Table 32: Opdivo pivotal trial data in head and neck cancer
  • Table 33: Opdivo ongoing late-phase trials in head and neck cancer
  • Table 34: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 35: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 36: Opdivo drug profile
  • Table 37: Opdivo pivotal trial data in urothelial bladder cancer
  • Table 38: Opdivo ongoing late-phase trials in urothelial bladder cancer
Back to Top